Search

everythinglearnresearchcommunity

for

Search:↓

ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.

JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

New pyridine compounds effectively inhibit GSK3, a diabetes treatment target.

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

Janus kinase inhibitors may effectively treat resistant scalp conditions like folliculitis decalvans and dissecting cellulitis.

Drugs that block GSK-3 show promise for treating various diseases.

JAK1 inhibitors can help reduce itchiness in atopic dermatitis.

JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.

Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

JAK inhibitors show promise for treating skin diseases effectively and safely.

Protein Kinase C shows promise for cancer treatment, but more research is needed to develop effective inhibitors.

Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.

JAK inhibitors can effectively reverse hair loss in people with alopecia areata.

JAK inhibitors show promise for treating hair loss in alopecia areata but need more clinical trials to confirm safety and effectiveness.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.

JAK inhibitors may help improve symptoms in adults with APECED.

Janus kinase inhibitors are promising for treating scarring alopecia, but more research is needed for safety and personalized treatments.

Sgk3 is essential for normal hair follicle growth and maintenance.

Janus kinase inhibitors are effective and generally safe for treating hair loss in adults with alopecia areata.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

JAK inhibitors help with skin conditions but need more research on dosing and safety.

CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.